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Resistance, toxicity and virologic failure have underlined the need to develop new HIV inhibitory 
products. Base on the natural bacteria “restriction modification system” antiviral immune model, we set 
out to analyze the effects of various restriction enzymes on the HIV genome. A computer simulated 
model using Web cutter Version 2.0, and cytogenetic analysis. 339 restriction enzymes from Promega 
database, 10 HIV-1/SIVcpz genes, 10 HIV-2/SIVsmm genes and 10 other SIV genes.  Gene sequences 
were fed into Web cutter 2.0 set to search enzymes with at least 6 recognition base pairs (palindromes). 
A background in vitro cytogenetic control analysis using HIV-1/SIVcpz GAG, POL and ENV genes was 
done. Of the 339 enzymes used, 238 (70.2%) cleaved the HIV-1/SIVcpz A1.BY.97.97BL006_AF193275 
genome with 9037 bp compared to 225 (66.4%) and 219 (64.6%) for the HIV-2/SIVsmm genome (9713 bp) 
and other SIV B.FR.83.HXB2_LAI_IIIB_BRU_K03455 genome (9719 bp), respectively. Individual genes 
had differing but potent susceptibility to the enzymes, with a 98.9% Web cutter PPV (95%CI, 97.2%-
99.6%) for in vitro cytogenetics. The natural bacteria RMS antiviral immune model offers precursors for 
developing novel HIV and other viral therapeutic molecules. 
 






Over two decades since the first case of Acquired Immu-
nodeficiency Syndrome (AIDS) was clinically described 
(CDC. Pneumocystis pneumonia- Los Angeles MMWR, 
1981), the syndrome still has no cure, and global infec-
tion rates have soared from epidemic to pandemic levels 
(Fanci, 1999; Joint UNAIDS/WHO, 1997; WHO. Remo-
ving obstacles to health development. Geneva, 1999; 
UNAIDS. Report on the global HIV-AIDS epidemic, 
2002). Human Immunodeficiency Virus (HIV), the virus 
that causes AIDS, survives and reproduces in vivo by inc-
orporating its genome into that of susceptible human cells 
(Cains and Souza 1998; Levy, 1996; Rosenberg et al., 
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interventions have been developed using the principle of 
inhibiting this replication cycle (Challand et al., 1997; 
Mansky and Temin, 1995). The international AIDS Socie-
ty, USA current treatment options include three drug 
classes: two Reverse Transcriptase inhibitor classes (the 
Nucleoside RTI; NRTIs and the Non-nucleoside RTIs; 
NNRTI classes), and the Protease Inhibitors; PIs, with the 
Integrase (fusion) Inhibitor MK-0508 (DHHS. Guidelines 
for the use of antiretroviral agents in HIV-1-infected 
adults and adolescents, 2006; Hammer et al., 2006; 
Bartlett et al., In press; Bartlett et al., 2001). However, 
resistance, toxicity and virologic failure have underlined 
the need to develop newer HIV inhibitory products (Man-
sky et al., 1995), and newer products such as chemokine 
receptor inhibitors and monoclonal antibody entry inhibi-
tors are in final clinical trials (Mayer et al., 2006; Gulick et 
al., 2006;   Sansone  et  al.,  2006;  Pugach  et  al.,  2006;  




Anastasopoulou et al., 2006; Norris et al.,  2005; Norris et 
al., 2006; Davison et al., 2006; Delmedico et al., 2006; 
Markowitz et al., 2006).    
Gene therapy offers another line of therapeutic interv-
ention, and as of to day, the use of U1snRNAs to inhibit 
gene expression (Sajic et al., 2006), RNA interference 
pathway to stop early and late HIV replication through 
post transcriptional gene slicing (Barichievy et al., 2006; 
Meshcheryakova et al., 2006), autologous T cell anti-HIV 
anti-sense Ribonucleic acid (RNA) delivered by the 
VRX496 lentiviral vector (Rebello et al., 2006), and rib-
ozyme enzymes cleaving HIV RNA(Liu et al., 2006) are 
being developed. Naturally, bacteria have a remarkable 
immunity to viral infection. Through the operation of a 
special enzyme system called the Restriction Modification 
System (RMS), whose main biological role is to protect 
the bacteria cell from incoming foreign deoxyribonucleic 
acid (DNA), many bacteria are rendered immune to viral 
tropism. Four types of RMS exist, with over 2,000 rest-
rictions enzymes isolated and tested. Most of the 
enzymes found in nature are however attributed to the 
type I and II RMS, which systems comprise of two enzy-
mes: a specific restriction endonuclease and a specific 
DNA methyltransferase. Both enzymes of this system 
recognize the same 4-8 base pair nucleotide sequence in 
the invading DNA with the former catalyzing cleavage of 
foreign double standard DNA and the later functioning to 
protect the host genomic DNA from cleavage by the 
cognate restriction enzyme (Murray, 2000; Nelson et al., 
1972; Roberts and Macelis, 1991; Janulaitis et al., 1992; 
Kessler and Manta, 1990; Nelson and McClelland, 1991; 
Radasci and Bickle, 1996; Barcus and Murray, 1995) 
We designed computer simulated assays with a backg-
round cytogenetic analysis control aimed at identifying 
which enzymes are active against the HIV genome as a 
means of identifying precursors for a restriction enzyme 
based HIV inhibitory product (Misaki,  
www.aegis.org/news/nv/2005/NV050301.html), and pres-







Computer simulated analysis employing web cutter Version 2.0 
preset to analyze linear nucleotide sequences for frequency of 
restriction enzyme cuts and site mapping of recognition sequences 
greater than 6 base pairs (bp) (Makerere Develops a Model for an 
AIDS Cure, Web cutter Version 2.0. 
http://rna.lundberg.gu.se/cutter2/), followed by a control cytogenetic 
analysis employing HIV-1/ Simian Immunodeficiency Virus (SIV) 
cpz POL, GAG and ENV genes 
 
 
Enzymes and genes 
 
339 restriction enzymes accessed from the Promega (Promega 
Corp. http://www.promega.com/default.asp) data base, HIV genes 






INDEX.html): 3 HIV whole genomes (HIV-1/SIVcpz 
A1.BY.97.97BL006_AF193275 genome with 9037 bp, HIV-
2/SIVsmm A.GM.x.MCN13_AY509259 genome with 9713 bp, and 
other SIV B.FR.83.HXB2_LAI_IIIB_BRU_K03455 genome with 
9719 bp), 10 HIV-1/SIVcpz genes [LTR; 
A1.CD.97.97ZR49_AF196750 (632 bp), GAG; 
A.KE.97.M104gag_AY772953 (1506 bp), POL; 
A1.TZ.01.A341_AY253314 (3012 bp), ENV; 
A.CD.97.KCC2_AJ401034 (2589 bp), VIF; 
A.CD.97.KCC2_AJ401034 (579 bp), TAT; 
A1.BY.97.97BL006_AF193275 (308 bp), REV; 
A1.TZ.01.A341_AY253314 (372 bp), VPU/VPX; 
A1.BY.97.97BL006_AF193275(246 bp), VPR; 
A.UA.x.98UA0116_AF413973 (291 bp), and NEF; 
A1.BY.97.97BL006_AF193275(624 bp)], 10  HIV-2/SIVsmm genes 
[LTR; A.PT.x.1139D3_AY622982(380 bp), GAG; 
G.GH.00.GH31_AY396866 
(358 bp), ENV; MAC.US.x.239_M33262 (2640 bp), VIF; 
A.GM.x.MCN13_AY509259 (648 bp), TAT; 
A.GM.x.MCN13_AY509259 (393 bp), REV; 
A.GM.x.MCN13_AY509259 (324 bp), VPU/VPX; 
A.GM.x.MCN13_AY509259 (339 bp), VPR; 
A.GM.x.MCN13_AY509259 (318 bp) and NEF; 
MAC.US.x.239_M33262 (792 bp)] and 10 other SIV genes [LTR; 
B.FR.83.HXB2_LAI_IIIB_BRU_K03455 (634 bp), GAG; 
B.FR.83.HXB2_LAI_IIIB_BRU_K03455 (1503 bp), POL; 
B.FR.83.HXB2_LAI_IIIB_BRU_K03455 (3009 bp), ENV; 
B.FR.83.HXB2_LAI_IIIB_BRU_K03455 (2571 bp), VIF; 
B.FR.83.HXB2_LAI_IIIB_BRU_K03455 (579 bp), TAT; 
B.FR.83.HXB2_LAI_IIIB_BRU_K03455 (306) REV; 
B.FR.83.HXB2_LAI_IIIB_BRU_K03455 (351 bp), VPU/VPX; 
DRL.x.x.FAO_AY159321, VPR; A1.UG.85.U455_M62320 (291 bp) 
and NEF;  





Number of cutting enzymes, frequency of cuts, and site mapping of 
the recognition sequences. Positive Predictive value (PPV) of 





Of the 339 enzymes analyzed, 238 (70.2%) enzymes 
cleaved the HIV-1/SIVcpz genome as compared to 225 
(66.4%) and 219 (64.6%) for HIV-2/SIVsmm and other 
SIV whole genomes. For the individual genes, HIV-
1/SIVcpz: LTR 62 (18.3%), GAG 70 (20.7%), POL 118 
(34.8%), ENV 138 (40.7%), VIF 33 (9.7%), TAT 15 
(4.4%), REV 25 (7.4%), VPU/VPX 83 (24.5%), VPR 36 
(10.6%) and NEF 61 (18%);HIV-2/SIVsmm: LTR 24 
(7.1%), GAG 29 (8.6%), POL 129 (38.1%), ENV 150 
(44.3 %), VIF 54 (15.9%), TAT 67 (19.8%), REV 27 
(8.0%), VPU/VPX 39 (11.5%), VPR 52 (15.3%) and NEF 
61 (18.0%); and other SIV LTR 53 (15.6%), GAG 91 
(26.8%), POL 97 (28.6)%), ENV 102 (30.1 %), VIF 37 
(10.9%), TAT 38 (11.2%), REV 41 (12.1%), VPU/VPX 33 
(9.7%), VPR 41 (12.1%) and NEF 76 (22.4%); and other 
SIV. Details of number of cuts and enzymes cutting is 4 
or > times are shown in Tables 1, 2 and 3. Site Mapping 
for gene cleavage is demonstrated in Figure 1. For the in 
vitro cytogenetic analysis of actual HIV-1 GAG, ENV and 
POL  exposed   to  enzyme   activity,   69   (20.4%),   137 




Table 1. Table of enzyme activity on HIV-1/SIVcpz+. 
 
# Gene (size by base pairs) No. cutting enzymes; 













(1506 bp)   




7 [all 7BssT1I, DraII, Eco130I, 
EcoO109I, EcoT14I, ErhI and StyI) 










15 [11 (AccI, BbsI, Bbv16II, BpiI, BpuAI 
, BstX2I , BstXI , BstYI , DraI , MflI  and 
XhoII) cleaving four times, 2 (SfcI and 
BstSFI) cleaving five times,  and 2 










7 [1 (MslI ) cleaving four times, 4 
(BssT1I, Eco130I, ErhI and StyI) 
Cleaving five times, and 2 (BstSFI and 









































*N = Total enzymes analyzed (339).  




(40.4%) and 116 (34.2%) enzymes exhibited cleavage 
respectively, yielding a Web cutter positive predictive 
value (PPV) of 98.6% (95%CI, 97.2%-99.6%) for actual in 





Our results generally indicate that all human immuno-
defiency virus (HIV) genome are still highly susceptible to 
restriction enzyme activity, with HIV-1/SIVcpz (70.2%)  
and HIV-2/SIVsmm (66.4%)  being more susceptible than 
other simian immunodefiency virus (SIV) genomes 
(64.6%). Considering that HIV1 and 2 evolved from SIV, 
this could imply that the original native SIV had acquired 
minimal resistance to restriction enzyme activity, and the 
evolutionary crossover to humans came with a loss of 
some of this protective property. This means that precur-
sors from restriction  enzymes  have  a  high  potential  to 




Table 2. Table of enzyme activity on HIV-2/SIVsmm genes+. 
 
# Gene (size by base pairs) No. cutting enzymes; 
n  (%of N*) 
Freq. of cuts;number of 
enzyme 




















22 [14 (BalI, BsrDI, BssT1I, BstXI, 
CfrI, EaeI, Eco130I, EcoT14I, ErhI, 
MluNI, MscI, PpuMI, Psp5II and StyI) 
cleaving four times, 6(BstX2I, BstYI, 
DraII, EcoO109I, MflI and XhoII) 
cleaving five times, and 2 (AcsI and 
ApoI) cleaving nine times]. 
4. ENV MAC.US.x.239_M33262 
(2640 bp) 





7 [4 (BstX2I, BstYI, MflI and XhoII) 
cleaving four times, and 3 (BpmI, 










































*N=total enzymes analyzed (339).  




suppress or kill HIV with less resistance or virologic 
failure arising. 
Enzyme activity among individual enzyme genes demo-
nstrates that it is not the size of gene, but rather the 
presence of specificity palindromes that determines the 
number of cuts a particular enzyme will produce on any 
given HIV gene. This is especially an important fact, 
when we project these results to a future human gene 
therapy model for HIV, as it explains that although the 
genetic code is universal, as long as targeted cells do not 
contain the specificity palindrome, the human genome 
will be protected against the enzyme activity. This redu-
ces the risk of toxicity, without of course eliminating other 
shortcomings in the developing of effective gene therapy. 
If we consider the HIV-1/SIVcpz GAG, POL and ENV 
genes for instance, the largest genes in the entire geno-
me, by only looking at enzymes cleaving 4 or > times, we 
may be made to draw the wrong conclusion that the 
larger the gene, the more susceptible it is to enzyme 
activity (1503 bp/7, 3012 bp/15 and 2889 bp/7cuts > or 
=4). However, on further analysis, we see that the ENV 
gene (2889 bp) which is 423 bp less then POL (3012 bp) 
was susceptible to 20 more enzymes than the POL 
(138/118). To support  this  further,  the  GAG  gene  with  




Table 3. Table of enzyme activity on other SIV genes+. 
 
# Gene name( size by base pairs) No. cutting enzymes; 
n  (%of N*) 
Freq. of cuts; number 
of enzyme 




53 (15.6) 1;43 
2;6 
4;4 
4 [ all4enzyme(BstX2I, BstYI, 










3 [2 (AcsI and ApoI) cleaving 
four times, and 1(Eco57I) 











7 [4 (AccI, BstSFI, BstXI and 
SfcI) cleaving four time, 1 (DraI) 
cleaving five times, and 2 (AcsI 










11 [5 (BstX2I, BstYI, Eco57I, MflI 
and XhoII) cleaving four times, 
and  6 (BssT1I, BstSFI, Eco130I 


















41 (12.1) 1;34 
2;7 
0 
8. VPU/VPX  
DRL.x.x.FAO_AY159321 
(? bp) 





9. VPR  
A1.UG.85.U455_M62320 
(291 bp) 
41 (12.1) 1;33 
28 
0 
10. NEF  
B.FR.83.HXB2_LA1_IIIB_KO3455 
(621 bp) 




*N=total enzymes analyzed (339).  




1083 bp less than the ENV, had a similar susceptibility to 
enzymes cleaving 4 or > times. Moreover GAG had 7 
enzymes cutting 4 times, as compared to only 1 of ENV. 
More evidence for site specificity rather than size deter-
mining enzyme activity is demonstrated by the REV 
(372bp) and VPU/VPX (246) genes, with the larger REV 
gene having only 25 cutting enzymes in general compa-
red to 83 for the smaller VPU/VPX gene. Other issues of 
safety are dependant upon choice of enzyme gene deli-
very,  and although various ex vivo and in vivo gene 
transfer techniques exist, we believe that a recom-binant 
HIV viral vector whose pathogenesis gene, NEF has 
been removed to render it impotent, could offer a more 
targeted delivery. The pharmacokinetics of  gene  therapy  




                                           DraII                                 
          Eco57I                      PpuMI                   XcmI          
atgactgaagcaccaacagagtttcccccggaggatgggaccccaccgagggaaccaggggatgagtggataata base 
pairs 
tactgacttcgtggttgtctcaaagggggcctcctaccctggggtggctcccttggtcccctactcacctattat 1 to 75 
                                      EcoO109I                              
                                      Psp5II                                
                                                                          
                          HindIII                                           
gaaatcctgagaaaaataaagaaagaagctttaaagcattttgaccctcgcttgctaactgctcttggcaactat base pairs 
ctttaggactctttttatttctttcttcgaaatttcgtaaaactgggagcgaacgattgacgagaaccgttgata 76 to 150 
                                DraI                                        
                                                                            
                                                                         
                               AccB1I NarI HaeII Bbv12I Alw21I              
                               KasI BbiII EheI EcoICRI BanII PshBI      Ksp632I 
          XcmI                 Eco64I BsaHI BbeI AspHI FriOI AsnI Eco24I    
atccatactagacatggagacacccttgaaggcgccagagagctcattaatgtcctacaacgagccctcttcatg base 
pairstaggtatgatctgtacctctgtgggaacttccgcggtctctcgagtaattacaggatgttgctcgggagaagtac 151 to 
225                               BanI Msp17I Bsp143II Psp124BI VspI FriOI Eam1104I 
                               BshNI Hsp92I Ecl136II SacI BsiHKAI BanII EarI 
                                Hin1I AcyI BstH2I Eco24I SstI AseI          
  
                                   BalI                                     
             BsrBI                 MscI                                     
        Eco57I                   EaeI                                       
cacttcagagcgggatgtaggctctcaagaattggccaaacagggggaagaactcctttcccagctacatcgacc base pairs
gtgaagtctcgccctacatccgagagttcttaaccggtttgtcccccttcttgaggaaagggtcgatgtagctgg 226 to 300             
AccBSI              CfrI                                       
             BstD102I              MluNI                                    
                                                                            
cctagaaccatgcaataa  base pairs 
ggatcttggtacgttatt  301 to 318  
 
Figure 1.  Graphic map of 6 bps Palindromic recognition nucleotide sequences in the HIV-
1/SIVcpz VPR gene. Color key: cac = unrecoginsed VPR gene sequence, aagctt = 




is also dependant on the choice of delivery (Perelson et 
al., 1996; Preslson et al., 1997; Miller et al., 1993; Jolly, 
1994; Weissman et al., 1995; Ledley and Ledley, 1994). 
One property that adds value to the RMS model is that 
specificity genes from enzymes in the same class, say 
type I can recombine to yield specificity proteins with 
different specificity properties from the parent enzymes. 
This is a major tool for developing newer restriction 
enzymes with new specificities, and thus fighting HIV 
resistance (Murray, 2000; Nelson et al., 1972; Roberts 
and Macelis, 1991; Janulaitis et al., 1992; Kessler and 
Manta, 1990; Nelson and McClelland, 1991; Radasci and 
Bickle, 1996; Barcus and Murray, 1995; Misaki, Makerere 
Develops a Model for an AIDS Cure. 
www.aegis.org/news/nv/2005/NV050301.html). 
The options for developing an HIV drug or micro bioc-






Although HIV is addressed here as the primary target, the 
RMS model offers prospects for developing other antiviral 
and anti-virus induced tumor therapy. It is this concept, 
the use of the bacterial RMS model in developing antiviral 
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